BioMarin Pharmaceutical Inc. (0HNC.L)
USD 70.03
(-2.19%)
USD 70.03
(-2.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.41 Billion USD | 15.42% |
| 2022 | 2.09 Billion USD | 13.53% |
| 2021 | 1.84 Billion USD | -0.76% |
| 2020 | 1.86 Billion USD | 9.18% |
| 2019 | 1.7 Billion USD | 14.27% |
| 2018 | 1.49 Billion USD | 13.52% |
| 2017 | 1.31 Billion USD | 17.62% |
| 2016 | 1.11 Billion USD | 25.5% |
| 2015 | 889.89 Million USD | 18.49% |
| 2014 | 751.04 Million USD | 36.93% |
| 2013 | 548.48 Million USD | 9.54% |
| 2012 | 500.72 Million USD | 13.45% |
| 2011 | 441.35 Million USD | 17.3% |
| 2010 | 376.26 Million USD | 15.9% |
| 2009 | 324.65 Million USD | 9.5% |
| 2008 | 296.49 Million USD | 143.86% |
| 2007 | 121.58 Million USD | 44.38% |
| 2006 | 84.2 Million USD | 228.06% |
| 2005 | 25.66 Million USD | 37.7% |
| 2004 | 18.64 Million USD | 54.06% |
| 2003 | 12.1 Million USD | -13.07% |
| 2002 | 13.91 Million USD | 18.98% |
| 2001 | 11.69 Million USD | -5.09% |
| 2000 | 12.32 Million USD | 76.69% |
| 1999 | 6.97 Million USD | 481.33% |
| 1998 | 1.2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 708.65 Million USD | 9.22% |
| 2024 Q1 | 648.83 Million USD | 0.41% |
| 2024 Q3 | 733.86 Billion USD | 5.23% |
| 2023 Q4 | 646.2 Million USD | 10.28% |
| 2023 FY | 2.41 Billion USD | 15.42% |
| 2023 Q2 | 594.59 Million USD | 0.28% |
| 2023 Q3 | 585.96 Million USD | -1.45% |
| 2023 Q1 | 592.94 Million USD | 10.31% |
| 2022 FY | 2.09 Billion USD | 13.53% |
| 2022 Q1 | 519.35 Million USD | 15.46% |
| 2022 Q2 | 533.79 Million USD | 2.78% |
| 2022 Q4 | 537.53 Million USD | 6.37% |
| 2022 Q3 | 505.34 Million USD | -5.33% |
| 2021 FY | 1.84 Billion USD | -0.76% |
| 2021 Q3 | 408.74 Million USD | -18.53% |
| 2021 Q2 | 501.69 Million USD | 3.22% |
| 2021 Q1 | 486.03 Million USD | 7.5% |
| 2021 Q4 | 449.81 Million USD | 10.05% |
| 2020 Q1 | 502.06 Million USD | 10.48% |
| 2020 FY | 1.86 Billion USD | 9.18% |
| 2020 Q2 | 429.48 Million USD | -14.46% |
| 2020 Q3 | 476.78 Million USD | 11.01% |
| 2020 Q4 | 452.11 Million USD | -5.17% |
| 2019 Q4 | 454.44 Million USD | -1.44% |
| 2019 Q1 | 400.74 Million USD | 13.46% |
| 2019 Q2 | 387.76 Million USD | -3.24% |
| 2019 FY | 1.7 Billion USD | 14.27% |
| 2019 Q3 | 461.09 Million USD | 18.91% |
| 2018 Q4 | 353.21 Million USD | -9.83% |
| 2018 Q3 | 391.7 Million USD | 5.06% |
| 2018 Q2 | 372.84 Million USD | -0.16% |
| 2018 Q1 | 373.44 Million USD | 4.23% |
| 2018 FY | 1.49 Billion USD | 13.52% |
| 2017 Q4 | 358.3 Million USD | 7.23% |
| 2017 Q2 | 317.44 Million USD | 4.51% |
| 2017 Q3 | 334.14 Million USD | 5.26% |
| 2017 Q1 | 303.74 Million USD | 1.22% |
| 2017 FY | 1.31 Billion USD | 17.62% |
| 2016 Q3 | 279.89 Million USD | -6.74% |
| 2016 Q4 | 300.09 Million USD | 7.22% |
| 2016 Q2 | 300.13 Million USD | 26.78% |
| 2016 Q1 | 236.73 Million USD | 3.86% |
| 2016 FY | 1.11 Billion USD | 25.5% |
| 2015 Q1 | 203.26 Million USD | -11.95% |
| 2015 Q4 | 227.93 Million USD | 9.11% |
| 2015 FY | 889.89 Million USD | 18.49% |
| 2015 Q3 | 208.9 Million USD | -16.61% |
| 2015 Q2 | 250.52 Million USD | 23.25% |
| 2014 Q2 | 191.78 Million USD | 26.55% |
| 2014 Q4 | 230.85 Million USD | 30.54% |
| 2014 FY | 751.04 Million USD | 36.93% |
| 2014 Q1 | 151.55 Million USD | 3.19% |
| 2014 Q3 | 176.84 Million USD | -7.79% |
| 2013 Q1 | 127.92 Million USD | -3.04% |
| 2013 Q4 | 146.87 Million USD | 7.31% |
| 2013 FY | 548.48 Million USD | 9.54% |
| 2013 Q3 | 136.87 Million USD | 0.05% |
| 2013 Q2 | 136.81 Million USD | 6.94% |
| 2012 Q1 | 116.64 Million USD | 8.16% |
| 2012 FY | 500.72 Million USD | 13.45% |
| 2012 Q4 | 131.93 Million USD | 2.98% |
| 2012 Q3 | 128.11 Million USD | 3.3% |
| 2012 Q2 | 124.01 Million USD | 6.32% |
| 2011 Q2 | 110.63 Million USD | 1.07% |
| 2011 Q1 | 109.45 Million USD | 7.72% |
| 2011 FY | 441.35 Million USD | 17.3% |
| 2011 Q4 | 107.84 Million USD | -4.92% |
| 2011 Q3 | 113.42 Million USD | 2.53% |
| 2010 FY | 376.26 Million USD | 15.9% |
| 2010 Q1 | 84.95 Million USD | -2.44% |
| 2010 Q2 | 91.95 Million USD | 8.24% |
| 2010 Q3 | 97.75 Million USD | 6.31% |
| 2010 Q4 | 101.61 Million USD | 3.95% |
| 2009 FY | 324.65 Million USD | 9.5% |
| 2009 Q4 | 87.08 Million USD | 7.77% |
| 2009 Q1 | 73.98 Million USD | -25.48% |
| 2009 Q2 | 82.78 Million USD | 11.9% |
| 2009 Q3 | 80.8 Million USD | -2.39% |
| 2008 Q2 | 64.17 Million USD | 6.26% |
| 2008 FY | 296.49 Million USD | 143.86% |
| 2008 Q1 | 60.39 Million USD | 34.65% |
| 2008 Q4 | 99.27 Million USD | 36.66% |
| 2008 Q3 | 72.64 Million USD | 13.2% |
| 2007 Q2 | 28.88 Million USD | 26.47% |
| 2007 Q1 | 22.83 Million USD | 3.72% |
| 2007 Q4 | 44.85 Million USD | 79.37% |
| 2007 FY | 121.58 Million USD | 44.38% |
| 2007 Q3 | 25 Million USD | -13.43% |
| 2006 Q4 | 22.01 Million USD | -11.67% |
| 2006 Q2 | 23.45 Million USD | 69.78% |
| 2006 Q1 | 13.81 Million USD | 45.77% |
| 2006 FY | 84.2 Million USD | 228.06% |
| 2006 Q3 | 24.92 Million USD | 6.3% |
| 2005 Q2 | 3.62 Million USD | -27.32% |
| 2005 FY | 25.66 Million USD | 37.7% |
| 2005 Q4 | 9.47 Million USD | 25.02% |
| 2005 Q3 | 7.57 Million USD | 109.02% |
| 2005 Q1 | 4.98 Million USD | -64.1% |
| 2004 FY | 18.64 Million USD | 54.06% |
| 2004 Q2 | 4.56 Million USD | 0.0% |
| 2004 Q3 | 181 Thousand USD | -96.03% |
| 2004 Q4 | 13.89 Million USD | 7577.9% |
| 2004 Q1 | - USD | 100.0% |
| 2003 Q1 | 3.49 Million USD | 11.52% |
| 2003 FY | 12.1 Million USD | -13.07% |
| 2003 Q4 | -15.59 Million USD | 0.0% |
| 2003 Q3 | - USD | -100.0% |
| 2003 Q2 | 12.1 Million USD | 246.11% |
| 2002 Q1 | 3.79 Million USD | 325.59% |
| 2002 Q3 | 3.56 Million USD | 4.27% |
| 2002 FY | 13.91 Million USD | 18.98% |
| 2002 Q4 | 3.13 Million USD | -12.16% |
| 2002 Q2 | 3.42 Million USD | -9.73% |
| 2001 Q2 | 3.66 Million USD | 7.76% |
| 2001 Q4 | 891 Thousand USD | -76.2% |
| 2001 Q3 | 3.74 Million USD | 2.18% |
| 2001 Q1 | 3.4 Million USD | 8.35% |
| 2001 FY | 11.69 Million USD | -5.09% |
| 2000 Q2 | 3.08 Million USD | -6.52% |
| 2000 Q1 | 3.29 Million USD | 44.9% |
| 2000 Q3 | 2.8 Million USD | -8.95% |
| 2000 FY | 12.32 Million USD | 76.69% |
| 2000 Q4 | 3.13 Million USD | 11.79% |
| 1999 Q3 | 2 Million USD | 25.0% |
| 1999 Q2 | 1.6 Million USD | -30.43% |
| 1999 Q4 | 2.27 Million USD | 13.8% |
| 1999 FY | 6.97 Million USD | 481.33% |
| 1999 Q1 | 2.3 Million USD | 0.0% |
| 1998 FY | 1.2 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -7641.771% |
| Myriad Genetics, Inc. | 678.4 Million USD | -256.608% |
| Evolus, Inc. | 202.08 Million USD | -1097.133% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -207.146% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 64.595% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -8919.222% |
| uniQure N.V. | 15.84 Million USD | -15169.999% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -28119.13% |
| bluebird bio, Inc. | 29.49 Million USD | -8101.6% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -69020.743% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -32.322% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -401.524% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -505.782% |
| Dynavax Technologies Corporation | 232.28 Million USD | -941.495% |
| Editas Medicine, Inc. | 78.12 Million USD | -2996.689% |
| FibroGen, Inc. | 147.75 Million USD | -1537.356% |
| Geron Corporation | 237 Thousand USD | -1020670.464% |
| Blueprint Medicines Corporation | 249.38 Million USD | -870.096% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 83.855% |
| Illumina, Inc. | 4.5 Billion USD | 46.287% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -203367.283% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -28.198% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -11437.705% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -94.575% |
| Insmed Incorporated | 305.2 Million USD | -692.648% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -6569.127% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 36.14% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -298.213% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 98.362% |
| Waters Corporation | 2.95 Billion USD | 18.17% |
| Zoetis Inc. | 8.54 Billion USD | 71.685% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 94.355% |
| Biogen Inc. | 9.83 Billion USD | 75.403% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -1272.751% |
| Nektar Therapeutics | 90.12 Million USD | -2584.39% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 48.036% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -794.023% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -1804.243% |
| Verastem, Inc. | - USD | -Infinity% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 75.487% |
| Imunon, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -1979.552% |
| Homology Medicines, Inc. | -6.65 Million USD | 36473.869% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 81.557% |
| OPKO Health, Inc. | 863.49 Million USD | -180.167% |
| Exelixis, Inc. | 1.83 Billion USD | -32.183% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -191.736% |
| TG Therapeutics, Inc. | 233.66 Million USD | -935.353% |
| Incyte Corporation | 3.69 Billion USD | 34.539% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -130.556% |